Reports received by FDA, by month

April 2026: adverse event reports received by FDA

127,219 drug reports (FAERS) and 303,173 device reports (MAUDE).

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

127,219
drug reports received: 105,698 a year earlier; 108,611
monthly average, preceding 12 months: 17.1% against the average; 303,173
device reports received: 204,562 a year earlier

FDA received 127,219 drug adverse event reports in April 2026, against 105,698 in the same month a year earlier and a monthly average of 108,611 over the preceding 12 months. The MAUDE device database received 303,173 reports that month (204,562 a year earlier). FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

The drugs listed most often as suspect products were Dupixent (12,300), Depo-Provera (7,718) and Ozempic (6,186), and the reactions recorded most often were meningioma (7,605), off label use (7,358) and drug ineffective (5,965).

Relative to their own average over the preceding 12 months, the drugs whose report count rose most were Depo-Provera (27.2× its average), Acthar (13.6× its average) and Ethinyl Estradiol Norelgestromin (9.1× its average). A jump in one month usually reflects a batch of reports from a manufacturer, a publicised event or a new product, not a change in what happens to patients.

Drug reports by month, three years to April 2026

Drugs listed most often as suspect products

Drug	Reports	Share of the month
Dupixent	12,300	9.7%
Depo-Provera	7,718	6.1%
Ozempic	6,186	4.9%
Zepbound	4,346	3.4%
Wegovy	3,883	3.1%
Bimzelx	2,130	1.7%
Mounjaro	2,020	1.6%
Skyrizi	1,436	1.1%
Prednisone	1,258	1%
Rituximab	1,186	0.9%
Lenalidomide	1,157	0.9%
Rinvoq	1,131	0.9%
Carboplatin	1,087	0.9%
Cyclophosphamide	1,056	0.8%
Nemluvio	941	0.7%

FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Largest rises against their own average

Drug	Reports this month	Times its 12-month average
Depo-Provera	7,718	27.2×
Acthar	500	13.6×
Ethinyl Estradiol Norelgestromin	582	9.1×
Vykat Xr	114	8.5×
Wegovy	3,883	7.8×
Brinsupri	501	7.7×
Briviact	145	6.1×
Lantus	787	5.7×

Drugs with at least 50 reports in the month and an average of at least 10 a month over the preceding year. A rise usually reflects a batch of manufacturer reports, a publicised event or a new product.

Reactions recorded most often

MedDRA term	Reports	Share of the month
Meningioma	7,605	6%
Off label useused for a purpose or in a way not on the label	7,358	5.8%
Drug ineffectivethe medicine did not work as expected	5,965	4.7%
Nauseafeeling sick	5,100	4%
Product dose omission issuea dose was missed	4,608	3.6%
Diarrhoealoose or frequent stools	4,098	3.2%
Deaththe patient died; cause not stated by this term	4,084	3.2%
Fatiguetiredness	4,049	3.2%
Pruritusitching	3,533	2.8%
Vomitingbeing sick	3,116	2.4%
Headachehead pain	2,924	2.3%
Rashskin rash	2,830	2.2%
Dyspnoeashortness of breath	2,770	2.2%
Product use in unapproved indicationused for a purpose not on the label	2,496	2%
Painpain, site not specified	2,444	1.9%

Devices named most often

Brand	Reports	Share of device reports
FreeStyle Libre 3	15,876	5.2%
FreeStyle Libre 3 Plus	15,792	5.2%
Dexcom G7 Continuous Glucose Monitoring System	13,893	4.6%
t:slim X2 Insulin Pump with Control-IQ Technology	10,304	3.4%
CareLink SmartSync Common App iOS	9,742	3.2%
MiniMed 780G US System BLE Connect 3.0 mg/dL	5,501	1.8%
Inset Guard	5,501	1.8%
t:slim X2 Insulin Pump with Control-IQ+ Technology	4,940	1.6%
iLet Bionic Pancreas	4,805	1.6%
FreeStyle Libre 2 Plus	3,815	1.3%

Questions about April 2026

How many adverse event reports did FDA receive in April 2026?

127,219 drug reports are in the openFDA FAERS release of 28 Sep 2026, and 303,173 device reports in the MAUDE release of 28 Sep 2026. The same month a year earlier has 105,698 drug reports.

Which drugs were listed most often?

Dupixent (12,300), Depo-Provera (7,718), Ozempic (6,186), Zepbound (4,346) and Wegovy (3,883).

Which reactions were recorded most often?

meningioma (7,605), off label use (7,358), drug ineffective (5,965), nausea (5,100) and product dose omission issue (4,608).

Can the count for a month still change?

Yes. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Older months change little.

Does a busy month mean something happened that month?

Not by itself. The date is when FDA received the report, not when the event occurred, and volume follows manufacturer batches, product launches and publicity. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.